Video

Dr. Zakharia on phase 2 study of durvalumab and RT in urothelial cancer

Yousef Zakharia, MD, discusses the design and results of a phase 2 trial that explored concurrent treatment with radiation and the PD-L1 inhibitor durvalumab (Imfinzi) followed by adjuvant durvalumab in patients with urothelial cancer. Zakharia is clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center.

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.